Psoriasis Club
  • Forum
  • Home
  • Portal
  • Member List
  • Psoriasis Score
  • PQOLS
  • What is psoriasis
  • Search
  • Help
Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members see a lot more than you)
wave
Login Register
Login
Username:
Password:
Lost Password?
 
Psoriasis Club › HealthHealth Boards › Psoriasis In The News v
« Previous 1 … 9 10 11 12 13 … 54 Next »

Galapagos announces phase 2 study

Linear Mode
Galapagos announces phase 2 study
Fred Offline
I Wanted To Change the World But Got Up Far Too Late.
Moderator
Posts: 66,958
Threads: 3,888
Joined: Aug 2011
Gender: Male
Location: France
Psoriatic Arthritis Score: 1
PQOLS: 1
Treatment: Bimzelx / Coconut Oil
#1
News  Tue-05-02-2013, 20:34 PM
Galapagos a clinical stage biotech company based in Belgium today announced that GlaxoSmithKline plan to initiate Phase 2 studies with GSK2586184 (formerly GLPG0778) in systemic lupus erythematosus (SLE) and chronic plaque psoriasis.

GSK2586184 is a selective JAK1 inhibitor which was discovered and developed within Galapagos’ osteoarthritis alliance with GSK. GSK in-licensed the molecule in February 2012, gaining worldwide rights to further development and commercialization. Galapagos is eligible, without further financial investment from Galapagos, to receive from GSK €34M in additional milestones plus up to double-digit royalties on global commercial sales of all therapeutic indications of GSK2586184.

“Inhibition of JAK1 is considered a promising new therapeutic route to treat inflammatory diseases. Galapagos is leading the field with two JAK1 inhibition molecules being tested in patients,” said Onno van de Stolpe, CEO of Galapagos. “With two of our JAK1 molecules in Phase 2, we hope that this will deliver a new class of medicines to patients with inflammatory diseases.”

GSK plans to initiate a 12 week, multi-center, dose-ranging, placebo-controlled Phase 2 study investigating safety and efficacy of various doses of GSK2586184 in SLE patients. Furthermore, GSK will also initiate a 12 week multi-center, dose-ranging, placebo-controlled Phase 2 study investigating the efficacy and safety of GSK2586184 in chronic plaque psoriasis.

Source: glpg.com
Quote
« Next Oldest | Next Newest »


Messages In This Thread
Galapagos announces phase 2 study - by Fred - Tue-05-02-2013, 20:34 PM
RE: Galapagos announces phase 2 study - by KatT - Sat-20-03-2021, 02:00 AM
RE: Galapagos announces phase 2 study - by Fred - Sat-20-03-2021, 11:35 AM
RE: Galapagos announces phase 2 study - by KatT - Sat-20-03-2021, 15:11 PM

Possibly Related Threads…
Thread Author Replies Views Last Post
News Otezla phase 3 study in moderate to severe genital psoriasis Fred 3 3,920 Wed-08-12-2021, 02:26 AM
Last Post: KatT
News Phase 2 study of PN-235 in psoriasis starts early 2022 Fred 0 2,031 Fri-03-12-2021, 13:44 PM
Last Post: Fred
News Evelo Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis Fred 0 1,973 Tue-28-09-2021, 20:59 PM
Last Post: Fred
News TYK2 inhibitor GLPG3667 phase 1b psoriasis study Fred 2 3,037 Tue-20-07-2021, 12:25 PM
Last Post: jiml
News Sonelokimab for psoriasis Phase 2b study Fred 2 3,758 Thu-06-05-2021, 19:30 PM
Last Post: Fred



Users browsing this thread: 1 Guest(s)
    About | Contact us | Login | Register | Home | Cookies/GDPR | RSS Syndication | Portal | Types Of Psoriasis | Psoriasis Score | Members Only Boards
    Copyright © 2010 - 2025 Psoriasis Club | All Rights Reserved | Founded May 2010 | Psoriasis Club Is Self Funded Without Sponsors Or Donations | Software by MyBB | Social
Linear Mode
Threaded Mode